NS1652
Selleck Chemicals
SKU:S2955-25MG
Couldn't load pickup availability

NS1652 is an inhibitor of VRAC used in studies of ion-channel pharmacology. In practice, this places the compound in experiments that measure ion conductance, membrane potential, and electrophysiological responses in cell signaling models. Dose-response comparison, orthogonal validation, and secondary assay follow-up can further sharpen mechanistic interpretation.
By inhibiting VRAC, NS1652 can be used to examine ion conductance, membrane potential, and electrophysiological responses. This target class is commonly examined through electrophysiology, ion-flux, and membrane-potential studies, together with downstream-response mapping. In cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving VRAC
- Concentration-response inhibition and target-dependence studies
- Electrophysiology, ion-flux, and membrane-potential studies
- Phenotypic profiling in cell signaling models
Overall, NS1652 is appropriate when a defined chemical perturbant is needed to connect VRAC with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- VRAC
- Target Class:
- Ion Channel
- Research Area:
- Cell Signaling
- CAS No.:
- 1566-81-0
- Molecular Weight:
- 324.25
- Formula:
- C₁₅H₁₁F₃N₂O₃
- SMILES:
- OC(=O)C1=CC=CC=C1NC(=O)NC2=CC=CC(=C2)C(F)(F)F
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.